EBV-Autoimmune disease treatment that could expand overall MS treatment program options

Stuart SchlossmanFor the Benefit of the Patient, MS Research Study and Reports

 Created on Sunday, 26 March 2023 14:33

by Alan M Dattner, MD     doctordattner@gmail.com

 

I was excited to see the studies that showed a 32-fold increase in MS in recruits who became EBV positive[i]. Howard Weiner at Harvard has described targeting EBV to treat MS.[ii] Over 200 articles on PubMed discuss the link between EBV and MS.  NexImmune’s project to grow T-cells that destroy EBV infected B-cells[iii], also point to the potential value of treating EBV as a method of controlling MS. EBV appears to incite a cross-reactive attack by EBV protein EBNA against similar molecules related to nerve cells and the myelin sheath such as GlialCAM. [iv] Many other articles discuss EBV and cross-reactive antigens on related to nerve and brain tissue.

 

My interest was stimulated because I had developed a series of methods to treat severe autoimmune skin and generalized conditions that included targeting EBV with a combination of intestinal microbiome modifiers, as well as a diet and supplements to restore integrity of the intestinal barrier and inhibit EBV. I realized that this treatment program would likely be applicable to treating patients with MS and high levels of EBV reactivity.

Continue Reading

#EpsteinBarrVirus    #EBV    #MultipleSclerosis   #MS    #Neurology     

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews